13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • MASTERKEY-115

    Acronym: 

    MASTERKEY-115

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase II Tumour Stream Melanoma
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Melanoma
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Phase-2 study of talimogene laherparepvec in combination with pembrolizumab in subjects with unresectable/ metastatic stage IIIB-IVM1c melanoma who have progressed on prior Anti-PD-1 based therapy.

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Sue Yeend sue.yeend@sa.gov.au 08 8222 6148 R Roberts-Thomson Not Yet Recruiting